Bausch Health Companies (BHC) Non-Current Deferred Tax Liability (2010 - 2026)
Bausch Health Companies (BHC) posted Non-Current Deferred Tax Liability of $211.0 million for Q2 2026, up 17.88% sequentially from $179.0 million in Q1 2026, and up 46.53% YoY from $144.0 million in Q2 2025.
Bausch Health Companies (BHC) Non-Current Deferred Tax Liability (2010 - 2026) Analysis & Trends
Bausch Health Companies has reported Non-Current Deferred Tax Liability for 17 years, with the latest figure at $211.0 million in Q2 2026.
- Quarterly Non-Current Deferred Tax Liability rose 46.53% year-over-year to $211.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $211.0 million (up 46.53% YoY) and the FY2025 annual result came in at $147.0 million, down 62.88% from the prior year.
- Non-Current Deferred Tax Liability advanced to $211.0 million in Q2 2026 per BHC's latest filing, from $179.0 million in the prior quarter.
- Over five years, Non-Current Deferred Tax Liability peaked at $552.0 million in Q1 2022 and troughed at $134.0 million in Q1 2025.
- A 5-year average of $266.3 million and a median of $208.0 million in 2023 frame the typical range for Non-Current Deferred Tax Liability.
- The sharpest annual moves came in 2025 and 2026: Non-Current Deferred Tax Liability sank 62.88% in 2025, then jumped 46.53% in 2026.
- Over 5 years, Non-Current Deferred Tax Liability stood at $390.0 million in 2022, then dropped by 1.03% to $386.0 million in 2023, then increased by 2.59% to $396.0 million in 2024, then tumbled by 62.88% to $147.0 million in 2025, then jumped by 43.54% to $211.0 million in 2026.
- According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $211.0 million, $179.0 million, and $147.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Bausch Health Companies | 2.42 Bn | 586.38 Mn | 2.10 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 211.00 Mn |
| Jun 30, 2026 | 211.00 Mn |
| Mar 31, 2026 | 179.00 Mn |
| Mar 31, 2026 | 179.00 Mn |
| Dec 31, 2025 | 147.00 Mn |
| Dec 31, 2025 | 147.00 Mn |
| Sep 30, 2025 | 145.00 Mn |
| Sep 30, 2025 | 145.00 Mn |
| Jun 30, 2025 | 144.00 Mn |
| Jun 30, 2025 | 144.00 Mn |
| Mar 31, 2025 | 134.00 Mn |
| Mar 31, 2025 | 134.00 Mn |
| Dec 31, 2024 | 128.00 Mn |
| Dec 31, 2024 | 128.00 Mn |
| Sep 30, 2024 | 169.00 Mn |
| Sep 30, 2024 | 169.00 Mn |
| Jun 30, 2024 | 170.00 Mn |
| Jun 30, 2024 | 170.00 Mn |
| Mar 31, 2024 | 170.00 Mn |
| Mar 31, 2024 | 170.00 Mn |